| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erin A Bohula, Benjamin M Scirica, Silvio E Inzucchi, Darren K McGuire, Anthony C Keech, Steven R Smith, Estella Kanevsky, Sabina A Murphy, Lawrence A Leiter, Jamie P Dwyer, Ramon Corbalan, Christian Hamm, Lee Kaplan, Jose Carlos Nicolau, Ton Oude Ophuis, Kausik K Ray, Mikhail Ruda, Jindrich Spinar, Tushar Patel, Wenfeng Miao, Carlos Perdomo, Bruce Francis, Shobha Dhadda, Marc P Bonaca, Christian T Ruff, Marc S Sabatine, Stephen D Wiviot. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet (London, England). vol 392. issue 10161. 2019-02-05. PMID:30293771. |
lorcaserin, a selective serotonin 2c receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. |
2019-02-05 |
2023-08-13 |
Not clear |
| Stephen J Kohut, Jack Bergma. Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys. European journal of pharmacology. vol 840. 2019-01-22. PMID:30268662. |
preclinical studies indicate that lorcaserin (belviq®), an fda-approved serotonin 2 c receptor agonist, may be a promising medication for the treatment of stimulant addiction. |
2019-01-22 |
2023-08-13 |
human |
| Stephen J Kohut, Jack Bergma. Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys. European journal of pharmacology. vol 840. 2019-01-22. PMID:30268662. |
these results indicate that serotonin 2 c receptor agonists, such as lorcaserin, have behaviorally selective effects on iv self-administration behavior, and deserve further consideration as candidates for the management of opioid use disorder. |
2019-01-22 |
2023-08-13 |
human |
| Luke K Burke, Emmanuel Ogunnowo-Bada, Teodora Georgescu, Claudia Cristiano, Pablo B Martinez de Morentin, Lourdes Valencia Torres, Giuseppe D'Agostino, Christine Riches, Nicholas Heeley, Yue Ruan, Marcelo Rubinstein, Malcolm J Low, Martin G Myers, Justin J Rochford, Mark L Evans, Lora K Heisle. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Molecular metabolism. vol 6. issue 10. 2018-12-12. PMID:29031711. |
recent reports indicate that the obesity medication lorcaserin, a 5-hydroxytryptamine (5-ht, serotonin) 2c receptor (5-ht |
2018-12-12 |
2023-08-13 |
Not clear |
| Gregory T Collins, Charles P Franc. Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys. Experimental and clinical psychopharmacology. vol 26. issue 5. 2018-12-11. PMID:29952618. |
two such drugs, lorcaserin (belviq; a drug with serotonin [5-ht]2c receptor agonist properties) and buspirone (buspar; a drug with 5-ht1a receptor partial agonist and dopamine d3/d4 receptor antagonist properties) can produce modest decreases in cocaine self-administration in rhesus monkeys. |
2018-12-11 |
2023-08-13 |
monkey |
| Erin A Bohula, Stephen D Wiviott, Darren K McGuire, Silvio E Inzucchi, Julia Kuder, KyungAh Im, Christina L Fanola, Arman Qamar, Conville Brown, Andrzej Budaj, Armando Garcia-Castillo, Milan Gupta, Lawrence A Leiter, Neil J Weissman, Harvey D White, Tushar Patel, Bruce Francis, Wenfeng Miao, Carlos Perdomo, Shobha Dhadda, Marc P Bonaca, Christian T Ruff, Anthony C Keech, Steven R Smith, Marc S Sabatine, Benjamin M Sciric. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. The New England journal of medicine. vol 379. issue 12. 2018-10-12. PMID:30145941. |
lorcaserin, a selective serotonin 2c receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. |
2018-10-12 |
2023-08-13 |
Not clear |
| David S Jacobs, Claire E Barkin, Michelle R Kohut, Jack Bergman, Stephen J Kohu. Effects of lorcaserin (Belviq Drug and alcohol dependence. vol 181. 2018-05-18. PMID:29040827. |
effects of lorcaserin (belviq accumulating evidence suggests that the fda-approved serotonin 5-ht |
2018-05-18 |
2023-08-13 |
Not clear |
| William R Shanahan, Jed E Rose, Alan Glicklich, Scott Stubbe, Matilde Sanchez-Ka. Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. vol 19. issue 8. 2018-03-12. PMID:27815511. |
lorcaserin is a selective serotonin 2c receptor agonist approved by the food and drug administration for chronic weight management. |
2018-03-12 |
2023-08-13 |
Not clear |
| Guy A Higgins, Leonardo B Silenieks, Amy Patrick, Ines A M De Lannoy, Paul J Fletcher, Linda A Parker, Neil J MacLusky, Laura C Sullivan, Teresa A Chavera, Kelly A Ber. Studies To Examine Potential Tolerability Differences between the 5-HT ACS chemical neuroscience. vol 8. issue 5. 2018-02-07. PMID:28338324. |
studies to examine potential tolerability differences between the 5-ht lorcaserin (lor) is a selective 5-ht |
2018-02-07 |
2023-08-13 |
Not clear |
| Katherine M Serafine, Kenner C Rice, Charles P Franc. Characterization of the discriminative stimulus effects of lorcaserin in rats. Journal of the experimental analysis of behavior. vol 106. issue 2. 2018-01-29. PMID:27640338. |
lorcaserin is approved by the food and drug administration for treating obesity and is under consideration for treating substance use disorders; it has agonist properties at serotonin (5-ht)2c receptors and might also have agonist properties at other 5-ht receptor subtypes. |
2018-01-29 |
2023-08-13 |
rat |
| Faidon Magkos, Elena Nikonova, Randi Fain, Sharon Zhou, Tony Ma, William Shanaha. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus. Obesity (Silver Spring, Md.). vol 25. issue 5. 2017-11-16. PMID:28345809. |
lorcaserin, a 5-ht |
2017-11-16 |
2023-08-13 |
Not clear |
| Ronald Christopher, Mike Morgan, Jim Ferry, Bhaskar Rege, Yong Tang, Allan Kristensen, William Shanaha. Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. Clinical therapeutics. vol 38. issue 10. 2017-09-28. PMID:27692638. |
lorcaserin is a serotonin 2c receptor agonist indicated for chronic weight management as an adjunct to diet and exercise. |
2017-09-28 |
2023-08-13 |
Not clear |
| Charles T Nguyen, Sharon Zhou, William Shanahan, Randi Fai. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Clinical therapeutics. vol 38. issue 6. 2017-09-18. PMID:27206567. |
lorcaserin is a selective serotonin 2c receptor (5-ht2c) agonist approved in the united states for use in chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. |
2017-09-18 |
2023-08-13 |
Not clear |
| Charles T Nguyen, Sharon Zhou, William Shanahan, Randi Fai. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Clinical therapeutics. vol 38. issue 6. 2017-09-18. PMID:27206567. |
given a theoretic risk for this syndrome in patients administered lorcaserin either alone or in combination with certain serotonergic agents (eg, selective serotonin reuptake inhibitors [ssris] and serotonin-norepinephrine reuptake inhibitors [snris]), patients taking prohibited serotonergic agents were excluded from the phase iii clinical trials. |
2017-09-18 |
2023-08-13 |
Not clear |
| Kathryn M Hurren, Marissa W Dunha. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Expert opinion on drug metabolism & toxicology. vol 13. issue 8. 2017-08-07. PMID:28636828. |
lorcaserin is a serotonin 2c receptor antagonist that was fda approved in 2012. |
2017-08-07 |
2023-08-13 |
Not clear |
| Olivia M Farr, Jagriti Upadhyay, Anna Gavrieli, Michelle Camp, Nikolaos Spyrou, Harper Kaye, Hannah Mathew, Maria Vamvini, Anastasia Koniaris, Holly Kilim, Alexandra Srnka, Alexandra Migdal, Christos S Mantzoro. Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Diabetes. vol 65. issue 10. 2017-05-19. PMID:27385157. |
lorcaserin is a serotonin 5-hydroxytryptamine 2c receptor agonist effective in treating obesity. |
2017-05-19 |
2023-08-13 |
human |
| F L Greenway, W Shanahan, R Fain, T Ma, D Rubin. Safety and tolerability review of lorcaserin in clinical trials. Clinical obesity. vol 6. issue 5. 2017-02-22. PMID:27627785. |
lorcaserin is a novel selective serotonin 2c receptor agonist indicated by the us food and drug administration for chronic weight management in adults with obesity or overweight with ≥1 comorbidity. |
2017-02-22 |
2023-08-13 |
Not clear |
| Yehuda Handelsman, Randi Fain, Zhixiao Wang, Xuan Li, Ken Fujioka, William Shanaha. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss. Postgraduate medicine. vol 128. issue 8. 2017-02-06. PMID:27659698. |
lorcaserin is a serotonin 2c receptor agonist approved for chronic weight management. |
2017-02-06 |
2023-08-13 |
Not clear |
| Richard Nesto, Randi Fain, Yuhan Li, William Shanaha. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgraduate medicine. vol 128. issue 4. 2017-01-26. PMID:27116910. |
lorcaserin is a selective 5-ht2c (5-hydroxytryptamine 2c) receptor agonist indicated for weight management. |
2017-01-26 |
2023-08-13 |
Not clear |
| Abu J M Sadeque, Safet Palamar, Khawja A Usmani, Chuan Chen, Matthew A Cerny, Weichao G Che. Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation. Drug metabolism and disposition: the biological fate of chemicals. vol 44. issue 4. 2016-12-13. PMID:26758853. |
lorcaserin [(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine] hydrochloride hemihydrate, a selective serotonin 5-hydroxytryptamine (5-ht) 5-ht(2c) receptor agonist, is approved by the u.s. food and drug administration for chronic weight management. |
2016-12-13 |
2023-08-13 |
human |